CitiusTech appoints Dhaval Shah to Chief Business Officer – MedTech & Life Sciences

IMT News Desk
IMT News Desk
· 2 min read
CitiusTech has appointed founding leader Dhaval Shah to Chief Business Officer – MedTech & Life Sciences, strengthening market strategy and client partnerships across its medical technology and life sciences businesses.

CitiusTech today announced the promotion of Dhaval Shah to Chief Business Officer – MedTech & Life Sciences, underscoring the company’s focus on deep domain expertise and growth in its core healthcare segments. In this strategic leadership position, Shah will lead enterprise market strategy, strengthen client partnerships, and drive business performance across CitiusTech’s Medical Technology and Life Sciences businesses.

A founding employee of CitiusTech, Shah has been integral to the company’s growth trajectory for more than 19 years. Over this period, he has played a key role in shaping CitiusTech’s offerings and expanding its presence with global healthcare and life sciences clients. He currently oversees a substantial portion of the company’s business. He leads relationships with more than 50 MedTech and Life Sciences clients, reflecting his long-standing engagement with the sector’s leading organisations.

Shah also serves as a member of the CitiusTech Executive Council, the company’s six-member executive management team, where he contributes to defining and steering the organisation’s overall strategic direction. His elevation to Chief Business Officer is positioned to further align CitiusTech’s MedTech and Life Sciences growth plans with its broader enterprise objectives.

With over 26 years of experience across HealthTech, imaging ISVs, providers, life sciences and medical device companies, Shah brings a wide-ranging perspective on healthcare innovation and commercial strategy. He is widely recognised as a thought leader in the healthcare and life sciences sectors and is committed to advancing healthcare transformation through innovative solutions that enhance experience, accessibility and affordability. He frequently shares his insights through industry articles and speaking engagements, engaging stakeholders across the healthcare ecosystem.

Before joining CitiusTech, Shah founded a boutique healthcare consulting firm and held senior roles serving large healthcare providers and healthcare technology organisations, giving him hands-on experience in addressing complex clinical, operational and technology challenges. He holds both a bachelor’s and a master’s degree in biomedical engineering from Wright State University, underpinning his technical expertise and deep understanding of healthcare technology.

Shah is based in the Princeton, New Jersey area, supporting CitiusTech’s engagement with clients and partners across key global markets as he steps into his expanded leadership role.

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk